BIENAIME JEAN JACQUES 4

What Happened

• Jean Jacques Bienaime, a director of Immunome, Inc. (IMNM), received a grant of 9,897 derivative shares (reported as an "A" award) on June 10, 2026. The filing reports an acquisition price of $0.00 and a reported value of $0 for the transaction. This is a compensatory award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (timely filing).
• Amount: 9,897 derivative shares granted; reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: The award vests in four equal quarterly installments starting June 10, 2026 and concluding on the one‑year anniversary (subject to continuous service).
• Filing timeliness: filed within two business days of the transaction (no late-filing flag).

Context

• This was a grant of derivative securities (an equity award) rather than a cash purchase or a sale — a common form of executive/director compensation. The award will vest over the next year; no exercise or sale of shares was reported at grant. Such awards primarily reflect compensation arrangements and do not by themselves indicate an insider buying or selling stock in the open market.